がん生物学的療法市場- 世界の産業規模、シェア、動向、機会、予測、製品別、流通チャネル別、地域別、競争別セグメント、2020～2030年

がん生物学的療法の世界市場規模は2024年に1,120億8,000万米ドルで、予測期間中のCAGRは7.69%で2030年には1,479億2,000万米ドルに達すると予測されています。

世界のがん生物学的療法市場とは、モノクローナル抗体、サイトカイン、ワクチンなどの生物学的薬剤を利用してがん細胞を標的として闘う、急速に発展しているがん治療セグメントを指します。この市場は、バイオテクノロジーの進歩や、がんの根底にある分子メカニズムに対する理解の深まりにより、長年にわたって大きな成長と革新を遂げてきました。がん遺伝学の理解が深まるにつれ、がん生物学的療法を個々の患者に合わせ、治療成果を最適化する個別化医療のアプローチが採用されるようになっています。がん患者の急増は、新規生物学的療法の臨床検査の増加を促しています。規制当局も有望な治療法を患者に迅速に提供するために承認プロセスを合理化しており、市場の成長をさらに促進しています。世界のがん生物学的療法市場は、アジア、ラテンアメリカ、中東の新興国が急成長を遂げるなど、伝統的市場以外にも拡大しています。医療のインフラが改善し、先進的ながん治療に対する認識が高まっていることが、この拡大に寄与しています。

市場促進要因

がん罹患率の上昇

主要市場課題

高コストとアクセスのしやすさ

主要市場動向

免疫療法革命の成長

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界のがん生物学的療法市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 製品別（がん増殖抑制剤、モノクローナル抗体、ワクチン）
  • 流通チャネル別（病院、小売店、通信販売薬局）
  • 地域別
  • 企業別（2024年）
• 市場マップ

第6章 北米のがん生物学的療法市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州のがん生物学的療法市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン

第8章 アジア太平洋のがん生物学的療法市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋：国別分析
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア

第9章 南米のがん生物学的療法市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカのがん生物学的療法市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 合併と買収（該当する場合）
• 製品の発売（該当する場合）

第13章 ポーターのファイブフォース分析

• 産業内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• F Hoffmann-La Roche Ltd
• Novartis AG
• Merck KgAa
• Amgen Inc
• GSK PLC
• Celgene Corporation
• Pfizer Inc
• Zydus Lifesciences Ltd
• Sun Pharmaceutical Industries Ltd
• Bayer AG

第15章 戦略的提言

第16章 調査会社について・免責事項

Global Cancer Biological Therapy Market was valued at USD 112.08 Billion in 2024 and is expected to reach USD 147.92 Billion by 2030 with a CAGR of 7.69% during the forecast period. The global cancer biological therapy market refers to the rapidly evolving field of cancer treatment that utilizes biological agents, such as monoclonal antibodies, cytokines, and vaccines, to target and combat cancer cells. This market has witnessed significant growth and innovation over the years due to advances in biotechnology and a growing understanding of the molecular mechanisms underlying cancer. As the understanding of cancer genetics deepens, personalized medicine approaches are being employed to tailor cancer biological therapies to individual patients, optimizing treatment outcomes. The surge in cancer cases has prompted an increase in clinical trials for novel biological therapies. Regulatory agencies have also streamlined approval processes to expedite promising treatments to patients, further facilitating market growth. The global cancer biological therapy market is expanding beyond traditional markets, with emerging economies in Asia, Latin America, and the Middle East witnessing rapid growth. Improved healthcare infrastructure and increasing awareness of advanced cancer treatments are contributing to this expansion.

Key Market Drivers

Rising Cancer Incidence

Cancer has long been one of humanity's most formidable adversaries, affecting millions of lives across the globe. Recent years have witnessed a troubling surge in cancer incidence rates, with the disease becoming an ever-increasing public health concern. Paradoxically, this ominous trend has also created an environment ripe for innovation and advancement in the field of cancer treatment, particularly in the realm of cancer biological therapies. According to data from the World Health Organization (WHO), the incidence of cancer has been steadily climbing, with millions of new cases diagnosed each year. In May 2022, the United Kingdom secured an $11.4 million grant to sustain its ongoing cancer research efforts.This upward trajectory is driven by a combination of factors, including an aging population, lifestyle changes, environmental factors, and improved cancer detection methods.

Key Market Challenges

High Costs and Accessibility

One of the significant barriers to the widespread adoption of biological therapies for cancer is their high cost. The development, production, and administration of these treatments are inherently expensive due to their complexity and the specialized nature of the technologies involved. Biological therapies, such as immunotherapies and targeted therapies, often require extensive research and clinical trials before they can be approved, further driving up costs. The manufacturing processes for these treatments, which often involve biologic agents like monoclonal antibodies or CAR-T cells, require highly sophisticated facilities and expertise, contributing to their high price tags.

For patients, the cost of these therapies can be prohibitive, especially in regions without comprehensive health insurance coverage. Even with insurance, co-pays, and out-of-pocket expenses can place a significant financial burden on families. This issue is exacerbated in low- and middle-income countries where healthcare infrastructure may be limited, and access to advanced treatments is scarce. The disparities in access to life-saving cancer therapies are glaring, creating a gap between wealthier populations who can afford cutting-edge treatments and those who cannot. The global challenge of ensuring equitable access to these therapies requires concerted efforts from governments, pharmaceutical companies, and healthcare providers. Policy interventions, such as price regulation, subsidies, and international collaborations to reduce costs, could help mitigate these disparities. Initiatives like patient assistance programs or public health campaigns aimed at increasing awareness of available treatments may further address these challenges. Until such systemic solutions are in place, the high cost and limited accessibility of cancer biological therapies will remain a critical issue, preventing many patients from benefiting from potentially life-saving treatments.

Key Market Trends

Growing Immunotherapy Revolution

Immunotherapy, a groundbreaking approach to cancer treatment, has ignited a revolution in the field of oncology. This remarkable advancement harnesses the body's immune system to fight cancer cells, providing hope to patients and transforming the landscape of cancer care. Immunotherapy represents a paradigm shift in cancer treatment. Unlike traditional therapies like chemotherapy and radiation, which directly target cancer cells, immunotherapy focuses on strengthening the body's own defenses against cancer. It stimulates the immune system to recognize and destroy cancer cells, offering several advantages.

Immunotherapy is highly precise. It targets only cancer cells while sparing healthy tissues, minimizing side effects. Some immunotherapies can induce durable responses, with the potential for sustained remission or even cures. Immunotherapy has expanded the arsenal of treatment options, particularly for advanced and hard-to-treat cancers. Immunotherapy has demonstrated efficacy in various cancer types, including melanoma, lung, bladder, and kidney cancers, among others. As research continues, the potential applications of immunotherapy are expected to grow, widening its reach in the market. Checkpoint inhibitors are a class of immunotherapies that block proteins that inhibit the immune response, allowing the immune system to recognize and attack cancer cells. Drugs like pembrolizumab (Keytruda) and nivolumab (Opdivo) have achieved remarkable success in clinical trials and have been approved for multiple indications, fueling market growth. CAR-T cell therapy is a type of immunotherapy that involves modifying a patient's T cells to express chimeric antigen receptors (CARs), which can recognize and target cancer cells. CAR-T therapies have shown exceptional results in treating certain blood cancers, such as leukemia and lymphoma. for instance, On November 16, 2023, the Food and Drug Administration approved enzalutamide (Xtandi, Astellas Pharma US, Inc.) for the treatment of non-metastatic castration-sensitive prostate cancer (nmCSPC) with biochemical recurrence at high risk for metastasis (high-risk BCR).

Key Market Players

• F Hoffmann-La Roche Ltd
• Novartis AG
• Merck KgAa
• Amgen Inc
• GSK PLC
• Celgene Corp
• Pfizer Inc
• Zydus Lifesciences Ltd
• Sun Pharmaceutical Industries Ltd
• Bayer AG

Report Scope:

In this report, the Global Cancer Biological Therapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cancer Biological Therapy Market, By Product:

• Cancer Growth Blockers
• Monoclonal Antibodies
• Vaccines

Cancer Biological Therapy Market, By Distribution Channel:

• Hospitals
• Retail & Mail Order Pharmacies

Cancer Biological Therapy Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • Germany
  • United Kingdom
  • France
  • Italy
  • Spain
• Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cancer Biological Therapy Market.

Available Customizations:

Global Cancer Biological Therapy market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validations
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cancer Biological Therapy Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Cancer Growth Blockers, Monoclonal Antibodies, Vaccines)
  • 5.2.2. By Distribution Channel (Hospitals, Retail & Mail Order Pharmacies) By Region
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Cancer Biological Therapy Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Distribution Channel
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Cancer Biological Therapy Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Distribution Channel
  • 6.3.2. Canada Cancer Biological Therapy Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Distribution Channel
  • 6.3.3. Mexico Cancer Biological Therapy Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Distribution Channel

7. Europe Cancer Biological Therapy Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Distribution Channel
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Cancer Biological Therapy Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Distribution Channel
  • 7.3.2. United Kingdom Cancer Biological Therapy Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Distribution Channel
  • 7.3.3. Italy Cancer Biological Therapy Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Distribution Channel
  • 7.3.4. France Cancer Biological Therapy Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Distribution Channel
  • 7.3.5. Spain Cancer Biological Therapy Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Distribution Channel

8. Asia-Pacific Cancer Biological Therapy Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Distribution Channel
  • 8.2.3. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Cancer Biological Therapy Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Distribution Channel
  • 8.3.2. India Cancer Biological Therapy Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Distribution Channel
  • 8.3.3. Japan Cancer Biological Therapy Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Distribution Channel
  • 8.3.4. South Korea Cancer Biological Therapy Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Distribution Channel
  • 8.3.5. Australia Cancer Biological Therapy Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Distribution Channel

9. South America Cancer Biological Therapy Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Distribution Channel
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Cancer Biological Therapy Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Distribution Channel
  • 9.3.2. Argentina Cancer Biological Therapy Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Distribution Channel
  • 9.3.3. Colombia Cancer Biological Therapy Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Distribution Channel

10. Middle East and Africa Cancer Biological Therapy Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Distribution Channel
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Cancer Biological Therapy Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Distribution Channel
  • 10.3.2. Saudi Arabia Cancer Biological Therapy Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Distribution Channel
  • 10.3.3. UAE Cancer Biological Therapy Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. F Hoffmann-La Roche Ltd
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Novartis AG
• 14.3. Merck KgAa
• 14.4. Amgen Inc
• 14.5. GSK PLC
• 14.6. Celgene Corporation
• 14.7. Pfizer Inc
• 14.8. Zydus Lifesciences Ltd
• 14.9. Sun Pharmaceutical Industries Ltd
• 14.10. Bayer AG

15. Strategic Recommendations

16. About Us & Disclaimer